

PURE BIOSCIENCE  
Form POS AM  
April 13, 2009

As filed with the Securities and Exchange Commission on April 13, 2009

Registration No. 333-133500

---

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1  
TO  
FORM SB-2 ON FORM S-1  
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

**PURE BIOSCIENCE**

(Exact name of registrant as specified in its charter)

**CALIFORNIA**  
(State or other jurisdiction of  
Incorporation or organization)

**2890**  
(Primary Standard Industrial  
Classification Code Number)

**33-0530289**  
(I.R.S. Employer Identification No.)

**1725 Gillespie Way, El Cajon, California 92020**  
**(619) 596 8600**

Address, including zip code, and telephone number,  
including area code, of registrant's principal executive offices)

**Scott M. Stanton**  
**R. Matthew Steiner**  
**Morrison & Foerster LLP**  
**12531 High Bluff Drive**  
**San Diego, CA 92130-2040**  
**(858) 720-5100**

(Address, including zip code, and telephone number,  
including area code, of agent for service)

**N/A**

(Approximate date of commencement of proposed sale to the public)

If any of the securities being registered in this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company)

Smaller reporting company

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM SB-2 ON FORM S-1 REGISTRATION STATEMENT UNDER



**DEREGISTRATION OF SECURITIES**

Pure Bioscience, a California corporation (the Registrant ), files this Post-Effective Amendment No. 1 to the following Registration Statement on Form SB-2 ( the Registration Statement ) and hereby deregisters all shares of common stock of the Registrant ( Common Stock ) unissued under the Registration Statement:

Registration Statement on Form SB-2 (File No. 333-133500), registering the sale of up to 8,157,376 shares of Common Stock of the Registrant and 1,020,220 shares of Common Stock of the Registrant issuable upon exercise of options and warrants by the selling securities holders named therein.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of El Cajon, State of California, on the dates indicated below.

**PURE BIOSCIENCE**

By: /s/ Michael L. Krall

Michael L. Krall, President/CEO/Principal Executive Officer  
April 13, 2009

By: /s/ Andrew J. Buckland

Andrew J. Buckland, CFO/Principal Financial Officer/Principal Accounting Officer  
April 13, 2009

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement has been signed below by the following persons in the capacities and on the dates indicated below.

| <u>NAME</u>   | <u>TITLE</u>                          | <u>DATE</u>    |
|---|---------------------------------------|----------------|
| <u>/s/ GREGORY BARNHILL</u><br>Gregory Barnhill           | Director                              | April 13, 2009 |
| <u>/s/ DENNIS BROVARONE</u><br>Dennis Brovarone           | Director                              | April 13, 2009 |
| <u>/s/ JOHN J. CARBONE, M.D.</u><br>John J. Carbone, M.D. | Director                              | April 13, 2009 |
| <u>/s/ MICHAEL L. KRALL</u><br>Michael L. Krall           | President/CEO and Director            | April 13, 2009 |
| <u>/s/ PAUL V. MAIER</u><br>Paul V. Maier                 | Director                              | April 13, 2009 |
| <u>/s/ DONNA SINGER</u><br>Donna Singer                   | Executive Vice President and Director | April 13, 2009 |
| <u>/s/ TOMMY G. THOMPSON</u><br>Tommy G. Thompson         | Director                              | April 13, 2009 |

